|
|
Volumn 331, Issue 7515, 2005, Pages 471-
|
|
Merck faces ongoing claims after Texan ruling on rofecoxib.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
LACTONE;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
SULFONE;
ARTICLE;
DRUG APPROVAL;
DRUG INDUSTRY;
LEGAL ASPECT;
LEGAL LIABILITY;
UNITED STATES;
CYCLOOXYGENASE INHIBITORS;
DRUG APPROVAL;
DRUG INDUSTRY;
LACTONES;
LIABILITY, LEGAL;
SULFONES;
TEXAS;
|
|
EID: 24744434636
PISSN: None
EISSN: 14685833
Source Type: Journal
DOI: 10.1136/bmj.331.7515.471 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
